Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.
Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...
StockStory.org on MSN
Pfizer earnings: What to look for from PFE
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors ...
Hosted on MSN
Pfizer lags as Cadrenal advances to Phase 3 trial
Pfizer shares remain under pressure amid declining COVID vaccine demand, looming patent expirations, and delays in entering the GLP-1 weight-loss market. Meanwhile, Cadrenal Therapeutics gained ...
Tempo's Fact Check team verified this claim by interviewing epidemiologists and comparing it with various credible sources.
S&P 500 Q1 earnings surge 27.1% as Alphabet, Apple, Amazon beat forecasts. Meta falls on AI capex fears. 128 firms report ...
Net absorption of lab space in the Bay Area turned negative in the first quarter, with 453K SF of occupancy losses, according ...
Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug ...
The incidence of allergic diseases has dramatically increased in the last decades. The dysregulation of our immune systems ...
That means in the absence of new, vaccine-evading coronavirus variants — a big if — next fall and winter could look a lot different in Canada in terms of the impact of COVID-19. Loading external pages ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results